Welcome to our dedicated page for Champions Oncolo news (Ticker: CSBR), a resource for investors and traders seeking the latest updates and insights on Champions Oncolo stock.
Champions Oncology, Inc. (CSBR) delivers cutting-edge solutions in personalized cancer research through its clinically validated tumorgraft and PDX platforms. This news hub provides investors and researchers with essential updates on the company’s scientific advancements, strategic partnerships, and operational milestones.
Access timely press releases covering key developments including clinical study results, technology licensing agreements, and regulatory progress updates. Our curated collection helps stakeholders track CSBR’s contributions to improving oncology drug development efficiency and patient-specific treatment strategies.
Discover updates across three core areas: platform innovations enhancing predictive cancer modeling, biopharma collaborations accelerating therapeutic discovery, and financial disclosures detailing sustainable growth. Each announcement is vetted for relevance to CSBR’s mission of transforming translational oncology research.
Bookmark this page for direct access to primary source materials from Champions Oncology. Regularly updated content ensures you stay informed about breakthroughs in patient-derived xenograft applications and their impact on precision medicine development.
Champions Oncology (CSBR), a global preclinical and clinical research services provider specializing in oncology solutions, has announced it will release its financial and operational results for the first quarter ended July 31, 2024, on Wednesday, September 11, 2024, after market close. The company will host a conference call to discuss the results at 4:30 P.M. EDT on the same day. Investors can join the call using the provided domestic and international dial-in numbers and access code. A replay of the call will be available via phone or through the company's website within 72 hours of the call.
Champions Oncology (Nasdaq: CSBR) reported its financial results for Q4 and fiscal year 2024. Q4 revenue increased 7% to $14 million, with an adjusted EBITDA income of $884,000. However, annual revenue decreased 7% to $50.2 million, with a fiscal year 2024 adjusted EBITDA loss of $3.9 million. The company faced challenges due to the biotech sector's funding environment and pharmaceutical spending patterns. Cost-cutting measures and operational efficiencies were implemented, showing positive results in Q4. Champions is optimistic about returning to consistent profitability in fiscal 2025. The company ended Q4 with a cash position of $2.6 million and no debt.
Champions Oncology (NASDAQ: CSBR), a global provider of preclinical and clinical research services, will announce its financial and operational results for Q4 and the fiscal year ended April 30, 2024, on July 18, 2024, after market close.
The company will hold a conference call at 4:30 P.M. EST (1:30 P.M. PST) to discuss the results. Participants can join the call domestically by dialing 888-506-0062 or internationally at 973-528-0011 using access code 135832. A replay will be available within 72 hours by dialing 877-481-4010 (Domestic) or 919-882-2331 (International), passcode: 50895, or through the investor section of the company's website.
Champions Oncology (CSBR) announced a strategic collaboration with Medicines Discovery Catapult (MDC) to boost the development of radiopharmaceutical therapeutics. This partnership leverages Champions' patient-derived models and pharmacology solutions with MDC's radiochemistry and multi-modal imaging expertise. The collaboration aims to advance radionuclide therapies, offering new hope for cancer patients. This synergy addresses the need for combined specialized expertise and clinically relevant models in radioligand therapies, positioning both organizations to drive significant advancements in the field.
FAQ
What is the current stock price of Champions Oncolo (CSBR)?
What is the market cap of Champions Oncolo (CSBR)?
